Skip to main content
. Author manuscript; available in PMC: 2014 Oct 15.
Published in final edited form as: J Neuroimmunol. 2013 Aug 1;263(0):20–27. doi: 10.1016/j.jneuroim.2013.07.009

Figure 2.

Figure 2

Figure 2

In vivo efficacies of MVBMOG/PLP and controls in suppressing MOG-induced EAE. PBS-treated mice (n = 12) received s.c. injections of 100 μl PBS on days 4, 7, and 10. MOG- (n = 6), MOG-BPI- (n = 5), and MVBMOG/PLP- (n = 12) treated mice received 100 nmol/100 μl PBS on days 4, 7, and 10 (s.c). The efficacy of each peptide was determined by (A) clinical disease score of EAE, expressed as the mean clinical score ± SEM, and (B) percent change in body weight, expressed as the mean % change in body weight ± SEM.